
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Viridian Therapeutics Inc (VRDN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VRDN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $37.94
1 Year Target Price $37.94
9 | Strong Buy |
5 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.95% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio - | 1Y Target Price 37.94 |
Price to earnings Ratio - | 1Y Target Price 37.94 | ||
Volume (30-day avg) 16 | Beta 0.48 | 52 Weeks Range 9.90 - 27.20 | Updated Date 08/15/2025 |
52 Weeks Range 9.90 - 27.20 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -1 | Actual -1 |
Profitability
Profit Margin - | Operating Margin (TTM) -142356% |
Management Effectiveness
Return on Assets (TTM) -39.77% | Return on Equity (TTM) -65.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1152724084 | Price to Sales(TTM) 4937.23 |
Enterprise Value 1152724084 | Price to Sales(TTM) 4937.23 | ||
Enterprise Value to Revenue 3779.42 | Enterprise Value to EBITDA -3.18 | Shares Outstanding 81662400 | Shares Floating 67246511 |
Shares Outstanding 81662400 | Shares Floating 67246511 | ||
Percent Insiders 0.16 | Percent Institutions 115.64 |
Upturn AI SWOT
Viridian Therapeutics Inc
Company Overview
History and Background
Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel therapies for patients suffering from serious diseases but currently no available approved products to sell. Founded in 2017, Viridian has focused on the development of treatments for thyroid eye disease (TED).
Core Business Areas
- Thyroid Eye Disease (TED) Therapeutics: Viridian focuses on developing novel antibody therapies for TED, an autoimmune disease causing inflammation and damage to tissues around the eyes.
Leadership and Structure
Scott Myers is the CEO. The company has a board of directors and operates with a typical biotechnology organizational structure, emphasizing research and development.
Top Products and Market Share
Key Offerings
- VRDN-001: VRDN-001 is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). It is being developed for the treatment of Thyroid Eye Disease. VRDN-001 is currently in Phase 3 clinical trials. Competitors include Tepezza (teprotumumab-trbw) by Horizon Therapeutics, a now Amgen company. Market share information for VRDN-001 is unavailable as it is not yet approved.
- VRDN-003: VRDN-003 is a new molecule under development. VRDN-003, an anti-IGF-1R antibody product candidate, is designed to potentially offer better convenience, tolerability, and efficacy than current therapies. Competitors are similar to VRDN-001, including Tepezza. Market share information is not available as VRDN-003 is not yet approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, focused on developing new therapeutics. The market for TED therapeutics is growing, driven by increased diagnosis rates and unmet medical needs.
Positioning
Viridian is positioned as an innovator in the TED therapeutic space, aiming to improve upon existing treatments with potentially more effective and convenient therapies.
Total Addressable Market (TAM)
The global TED market is projected to reach multi-billion dollars in the coming years. Viridian's success depends on the successful development and approval of their product candidates and being competive. Viridian aims to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates targeting IGF-1R for TED
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- No currently marketed products, resulting in no revenue stream
- High cash burn rate typical of development-stage biotech companies
Opportunities
- Potential to capture significant market share in the TED market
- Expansion into other autoimmune diseases
- Partnerships or acquisitions by larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from established players like Horizon Therapeutics(Amgen)
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- AMGN
Competitive Landscape
Viridian's advantage lies in developing potentially improved anti-IGF-1R antibodies. The primary disadvantage is that they don't have any approved products and compete against established players, now Amgen, with approved and marketed products.
Growth Trajectory and Initiatives
Historical Growth: Since its founding, Viridian's growth has been characterized by advancing its pipeline of therapeutic candidates through preclinical and clinical development stages.
Future Projections: Future growth is contingent upon the successful completion of clinical trials and regulatory approval of its product candidates. Analyst estimates vary, but positive trial outcomes could lead to significant stock appreciation.
Recent Initiatives: Recent initiatives include advancing VRDN-001 and VRDN-003 through clinical trials, presenting clinical data at scientific conferences, and securing financing to support ongoing R&D activities.
Summary
Viridian Therapeutics is a development-stage biotechnology company with promising therapeutic candidates for TED. The company is focusing its efforts on advancing VRDN-001 and VRDN-003 through clinical trials. A risk is if it doesn't get approved or it is outperformed by its competitors. Viridian's success depends on the positive clinical trial outcomes and market acceptance of its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viridian Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2014-06-18 | CEO, President & Director Mr. Stephen F. Mahoney J.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | |
Full time employees 143 |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.